...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Kinaxo Extends its Collaboration with Roche

| Print |
Tuesday, 12 January 2010 11:00 (UTC + 1)

Kinaxo_logo

Martinsried, Germany, January 12, 2010 / b3c newswire /KINAXO Biotechnologies GmbH announced today that it has entered into a second collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche. Financial details of the agreement were not disclosed.


KINAXO’s phosphoproteomics platform PhosphoScout® enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using state-of-the-art quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale. Unlike immunoassays, PhosphoScout® does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout® as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies.

 

 

About KINAXO - www.kinaxo.com
KINAXO Biotechnologies is a privately-held biotechnology service company based in Munich/Martinsried, Germany. KINAXO offers extensive experience in chemical proteomics and quantitative phosphoproteomics technologies for drug mode-of-action analysis, cellular target profiling, target deconvolution, and drug re-positioning.


KINAXO just completed a financing round and recently announced its collaboration with Bayer Vital GmbH for biomarker development, as well as renewing its ongoing agreement with Johnson & Johnson.

 

Contact
Dr. Jutta Fritz, MBA, Head of Technology and Business Development
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Phone +49 89 4613363-22
www.kinaxo.com